Pharmaceuticals, said, "CDI's human iPSC-derived neurons, iCell Neurons, offer unprecedented opportunities for drug discovery and development. The cells not only functionally express key ion channels and receptors but also form electrophysiologically active networks. These attributes of iCell Neurons help substantiate the possibility that these cells provide an exciting new human model of neuronal physiology that augments traditional ones, such as rat primary neurons and human neuronal cell lines."
iCell Neurons present a human platform that enables the modeling of healthy neuronal cells to improve the predictability of drug candidate efficacy and toxicity screens early in the pharmaceutical pipeline process. "The human brain represents a complex organ that has consistently proven difficult to model in vitro, and this is partially reflected in the lack of effective therapeutics to treat neurological diseases and disorders," said Chris Parker, Chief Commercial Officer. "Degenerative diseases, such as Alzheimer's, Parkinson's, and ALS, and genetic dispositions, such as Huntington's and muscular dystrophy, can also be modeled to better understand these disease states for drug discovery and eventual therapies."
Because iCell Neurons are human cells, they better recapitulate human biology. These cells are better predictors of drug candidate responses than current cell models, including immortalized cell lines and primary neurons isolated from rodent tissues, which present significant limitations in biological relevance, reproducibility, and scalability.
Robert Palay, Chief Executive Officer of CDI, said, "iCell Neurons are the third iPSC-derived product CDI has now commercially launched. We launched the first product ever developed from iPS cells,
SOURCE Cellular Dynamics International, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 112.
MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting3.
Orange and Medic4all Launched the Worlds First Cellular Tele-Health Service4.
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia5.
MIT, BU engineer cellular circuits that count events6.
New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers7.
Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement8.
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming9.
Cellular Dynamics International Reprograms Blood Cells into Stem Cells10.
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing11.
Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International